ATE245646T1 - Therapeutische nukleoside - Google Patents

Therapeutische nukleoside

Info

Publication number
ATE245646T1
ATE245646T1 AT93904248T AT93904248T ATE245646T1 AT E245646 T1 ATE245646 T1 AT E245646T1 AT 93904248 T AT93904248 T AT 93904248T AT 93904248 T AT93904248 T AT 93904248T AT E245646 T1 ATE245646 T1 AT E245646T1
Authority
AT
Austria
Prior art keywords
therapeutic nucleosides
nucleosides
therapeutic
preparation
relates
Prior art date
Application number
AT93904248T
Other languages
English (en)
Inventor
Susan Mary Daluge
Douglas Alan Livingston
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE245646T1 publication Critical patent/ATE245646T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93904248T 1992-02-25 1993-02-24 Therapeutische nukleoside ATE245646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929204015A GB9204015D0 (en) 1992-02-25 1992-02-25 Therapeutic nucleosides
PCT/GB1993/000378 WO1993017020A2 (en) 1992-02-25 1993-02-24 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
ATE245646T1 true ATE245646T1 (de) 2003-08-15

Family

ID=10711016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904248T ATE245646T1 (de) 1992-02-25 1993-02-24 Therapeutische nukleoside

Country Status (13)

Country Link
US (5) US5641889A (de)
EP (1) EP0628044B1 (de)
JP (1) JP3172533B2 (de)
KR (1) KR100282584B1 (de)
AT (1) ATE245646T1 (de)
AU (2) AU3571093A (de)
CA (1) CA2130755C (de)
DE (1) DE69333109T2 (de)
DK (1) DK0628044T3 (de)
ES (1) ES2203615T3 (de)
GB (1) GB9204015D0 (de)
PT (1) PT628044E (de)
WO (1) WO1993017020A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
ATE226437T1 (de) * 1993-06-10 2002-11-15 Univ Wake Forest (phospho)lipide zum bekämpfen einer hepatitis b- infektion
DE69402548T2 (de) * 1993-06-21 1997-07-17 Merrell Pharma Inc Carbocyclische nucleoside mittel nützlich als selektive inhibitoren von proinflammatorischen cytokinen
EP0630897A3 (de) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-Hydroxy-4-hydroxymethyl-2-methylen-cyclopentyl Purine und Pyrimidine.
WO1995022330A1 (en) * 1994-02-17 1995-08-24 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
DE69535758D1 (de) 1994-08-29 2008-07-03 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
WO1997045529A1 (de) * 1996-05-30 1997-12-04 Lonza Ag Verfahren zur herstellung von aminoalkoholen und derivaten davon
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
SK285229B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby derivátov (1R,4S)- alebo (1S,4R)-1-amino-4- (hydroxymetyl)-2-cyklopenténu a enantioméru (1R,4S)-N-butyryl-1- amino-4-(hydroxymetyl)-2-cyklopenténu
CZ298144B6 (cs) * 1997-11-27 2007-07-04 Lonza Ag Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
US6362225B1 (en) * 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
ES2218225T3 (es) * 1999-09-10 2004-11-16 Stichting Rega V.Z.W. Nucleosidos carbociclicos y procedimiento para obtenerlos.
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7038059B2 (en) 2000-10-18 2006-05-02 Kuraray Co., Ltd. Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
WO2003002565A1 (en) 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2463719A1 (en) 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US20070208042A1 (en) * 2006-03-03 2007-09-06 Sherwood Services Ag Method of using vasoconstrictive agents during energy-based tissue therapy
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
KR101925902B1 (ko) 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) * 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) * 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
CN103597856B (zh) 2011-04-14 2017-07-04 福纳克股份公司 听力工具
GB201513601D0 (en) * 2015-07-31 2015-09-16 Univ Liverpool Antiviral compounds
CN106220515A (zh) * 2016-08-12 2016-12-14 郸城巨鑫生物科技有限公司 一种(1r,4s)‑1‑氨基‑4‑羟甲基‑2‑环戊烯盐酸盐的合成方法
JP7084591B2 (ja) * 2017-03-29 2022-06-15 ヤマサ醤油株式会社 ヌクレオシド誘導体又はその塩、及びそれを含む医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60139653A (ja) * 1983-12-27 1985-07-24 Yoshitomi Pharmaceut Ind Ltd シクロペンテン誘導体
US4543255A (en) * 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
EP0219838A3 (de) * 1985-10-22 1988-04-06 Takeda Chemical Industries, Ltd. Carbocyclische Purin-Nukleoside, ihre Herstellung und Verwendung
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4734194A (en) * 1986-03-25 1988-03-29 The Upjohn Company Combined filter and valve mechanism
IN166499B (de) * 1987-02-12 1990-05-19 Takeda Chemical Industries Ltd
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
AU4829190A (en) * 1988-12-12 1990-07-10 Peter M. Palese Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
DK0424064T3 (da) * 1989-10-16 1995-06-26 Chiroscience Ltd Chirale azabicycloheptanoner og fremgangsmåde til fremstilling deraf
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0471057A4 (en) * 1990-03-06 1992-11-19 Virachem, Inc. Methods and compositions for the prophylaxis and treatment of cytomegalovirus infections
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
EP0628044B1 (de) 2003-07-23
KR950700298A (ko) 1995-01-16
GB9204015D0 (en) 1992-04-08
PT628044E (pt) 2003-12-31
JP3172533B2 (ja) 2001-06-04
US20010008946A1 (en) 2001-07-19
DK0628044T3 (da) 2003-11-17
JPH07504185A (ja) 1995-05-11
WO1993017020A2 (en) 1993-09-02
EP0628044A1 (de) 1994-12-14
DE69333109T2 (de) 2004-04-15
AU707075B2 (en) 1999-07-01
CA2130755A1 (en) 1993-08-26
KR100282584B1 (ko) 2001-02-15
US5808147A (en) 1998-09-15
US5840990A (en) 1998-11-24
US6392085B2 (en) 2002-05-21
AU3571093A (en) 1993-09-13
HK1003941A1 (en) 1998-11-13
US5641889A (en) 1997-06-24
US5919941A (en) 1999-07-06
ES2203615T3 (es) 2004-04-16
WO1993017020A3 (en) 1994-03-17
AU2489197A (en) 1997-08-28
DE69333109D1 (de) 2003-08-28
CA2130755C (en) 2004-03-30

Similar Documents

Publication Publication Date Title
ATE245646T1 (de) Therapeutische nukleoside
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
DE69324923D1 (de) Antiretrovirale, enantiomere Nukleotid-Analoge
FI913236A0 (fi) 9-purinylfosfonsyraderivat.
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
NO912874D0 (no) Fremgangsmaate for fremstilling av nye carbocykliske analoger av visse nucleosider.
DK0565631T3 (da) Antivirale forbindelser
ES2132419T3 (es) Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias.
SE9604582D0 (sv) Novel compounds
IT8721560A0 (it) Procedimento per la purificazione di interferone.
NO960849D0 (no) Difluorstaton-antivirale analoger
NO974512D0 (no) Fremgangsmåte for syntese av nukleosid-analoger
SE9603726D0 (sv) Novel compounds
IT1231506B (it) Procedimento per la purificazione di polieteri polioli.
AR240397A1 (es) Banera para aplicacion de hidromasajes por burbujeo.
SU1746666A1 (ru) Замещенные 3-аминометиленпирролидин-2,4-дионы, обладающие противосудорожной активностью
SU1279221A1 (ru) 3-Метил-1-(4-тиоцианатофенил)-5-(2-фурил-)-Δ-пиразолин, проявляющий противовоспалительную активность
KR890701586A (ko) 이환식 화합물, 이의 약제로서의 용도, 이의 제조방법 및 이의 제조에 유용한 중간체
IT8519884A0 (it) Procedimento per la purificazione di fruttosio.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0628044

Country of ref document: EP